Compare Essex Property Trust, Inc. (ESS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Moderna, Inc. — how do they compare? Essex Property Trust, Inc. trades at $273.22 (market cap $17.26B), while Moderna, Inc. trades at $220.84 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4.6× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ESS | MRNA | |
|---|---|---|
Market Cap | $17.26B | $78.65B |
Volume | 454,464 | 37,373,437 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $203.46 |
52-Week Low | $239.61 | $22.36 |
Typical Hold Time | 111 Days | — |
Enterprise Value | $23.86B | $74.80B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $273.21, up 1.93% today, but technical indicators signal a bearish trend with resistance near $273. The company reported mixed quarterly earnings, beating in Q1 but missing in Q2 and Q4 2025, while maintaining strong profitability with a net margin of 21.48%. Recent news highlights strong Q2 2026 results and the resolution of litigation, improving the risk profile.
The outlook is cautiously optimistic with a consensus price target of $303.41, implying upside, but risks include earnings volatility and high debt levels. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid ongoing operational execution challenges in the real estate sector.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
